DRTE Dendrite International (MM)

Dendrite International, Inc. (NASDAQ:DRTE), a leading provider of pharmaceutical industry solutions, today announced that the Company and its chairman and chief executive officer, John Bailye, have been honored at the tenth annual New Jersey Technology Council (NJTC) Gala Awards. Mr. Bailye won the John H. Martinson Technology Supporter Award, while Dendrite was inducted into NJTC�s prestigious Hall of Fame. The awards, which are given each year to recognize and celebrate New Jersey technology companies and their leaders for business accomplishments in technological innovation, were presented on November 16, 2006 at the New Jersey Performing Arts Center in Newark, NJ. Mr. Bailye was honored for his significant commitment to the support and advancement of technology in New Jersey. As an entrepreneur who moved Dendrite from Australia to the US in 1986, Mr. Bailye has continually demonstrated an innovative spirit and uncompromising drive to deliver leading pharmaceutical-specific solutions to its client base. Mr. Bailye�s other accolades have included the Ernst & Young�s New Jersey Software and Technology Entrepreneur of the Year, Business Review Weekly�s top 20 influential Australians in the United States, and the Golden Door Award from the New Jersey International Institute, which recognizes those who have come to the United States and achieved commercial success. Today, as a result of Mr. Bailye�s visionary leadership and deep pharmaceutical expertise, Dendrite serves clients in more than 50 countries, including the world�s top 20 pharmaceutical companies. �Since Dendrite�s inception 20 years ago, John has been the embodiment of innovation and visionary leadership,� said Joe Ripp, president and COO of Dendrite. �Recognition by the NJTC is an honor both for John and Dendrite and we�re proud to have Dendrite inducted into the NJTC Hall of Fame.� About Dendrite Founded in 1986, Dendrite International (NASDAQ:DRTE) enables sales, marketing, clinical and compliance solutions for the global pharmaceutical industry. The company has clients in more than 50 countries and includes the world's top 20 pharmaceutical companies. For more information, please visit www.dendrite.com. About NJTC The New Jersey Technology Council (NJTC) provides business support, networking opportunities, information, advocacy and recognition of technology companies and their leaders. Founded in 1996, NJTC's more than 1,200 member companies work together to support their own enterprises while advancing New Jersey's status as a leading technology center in the United States. For more information, please visit www.njtc.org. Note: Dendrite is a registered trademark of Dendrite International, Inc. This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements. Dendrite International, Inc. (NASDAQ:DRTE), a leading provider of pharmaceutical industry solutions, today announced that the Company and its chairman and chief executive officer, John Bailye, have been honored at the tenth annual New Jersey Technology Council (NJTC) Gala Awards. Mr. Bailye won the John H. Martinson Technology Supporter Award, while Dendrite was inducted into NJTC's prestigious Hall of Fame. The awards, which are given each year to recognize and celebrate New Jersey technology companies and their leaders for business accomplishments in technological innovation, were presented on November 16, 2006 at the New Jersey Performing Arts Center in Newark, NJ. Mr. Bailye was honored for his significant commitment to the support and advancement of technology in New Jersey. As an entrepreneur who moved Dendrite from Australia to the US in 1986, Mr. Bailye has continually demonstrated an innovative spirit and uncompromising drive to deliver leading pharmaceutical-specific solutions to its client base. Mr. Bailye's other accolades have included the Ernst & Young's New Jersey Software and Technology Entrepreneur of the Year, Business Review Weekly's top 20 influential Australians in the United States, and the Golden Door Award from the New Jersey International Institute, which recognizes those who have come to the United States and achieved commercial success. Today, as a result of Mr. Bailye's visionary leadership and deep pharmaceutical expertise, Dendrite serves clients in more than 50 countries, including the world's top 20 pharmaceutical companies. "Since Dendrite's inception 20 years ago, John has been the embodiment of innovation and visionary leadership," said Joe Ripp, president and COO of Dendrite. "Recognition by the NJTC is an honor both for John and Dendrite and we're proud to have Dendrite inducted into the NJTC Hall of Fame." About Dendrite Founded in 1986, Dendrite International (NASDAQ:DRTE) enables sales, marketing, clinical and compliance solutions for the global pharmaceutical industry. The company has clients in more than 50 countries and includes the world's top 20 pharmaceutical companies. For more information, please visit www.dendrite.com. About NJTC The New Jersey Technology Council (NJTC) provides business support, networking opportunities, information, advocacy and recognition of technology companies and their leaders. Founded in 1996, NJTC's more than 1,200 member companies work together to support their own enterprises while advancing New Jersey's status as a leading technology center in the United States. For more information, please visit www.njtc.org. Note: Dendrite is a registered trademark of Dendrite International, Inc. This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.